Facilitating medical withdrawal from opiates in rural Ontario

Rural and Remote Health

Volumn 12, Issue 4, 2012, Pages

  Kiepek, N ^a   Hancock, L ^a   Toppozini, D ^b   Cromarty, H ^b   Morgan, A ^b   Kelly, L ^a  

^a NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^b Sioux Lookout Meno Ya Win Health Centre   (Canada)

Author keywords

Addiction; Canada; First Nation; Medical withdrawal

Indexed keywords

NARCOTIC ANTAGONIST;

AMERICAN INDIAN; ARTICLE; CANADA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; CULTURAL COMPETENCE; ETHNOLOGY; FEMALE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT ATTITUDE; PREGNANCY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RURAL HEALTH CARE; STANDARD; STATISTICS; URBAN POPULATION; WITHDRAWAL SYNDROME;

AMERICAN NATIVE CONTINENTAL ANCESTRY GROUP; COUNSELING; CULTURAL COMPETENCY; FEMALE; HEALTH SERVICES, INDIGENOUS; HOSPITALIZATION; HUMANS; MALE; NARCOTIC ANTAGONISTS; ONTARIO; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; PREGNANCY; RURAL HEALTH SERVICES; SUBSTANCE WITHDRAWAL SYNDROME; URBAN POPULATION;

EID: 84873536215     PISSN: 14456354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Fischer B, Rehm J, Patra J, Cruz MF. Changes in illicit opioid use across Canada. Canadian Medical Association Journal 2006; 175(11): 1385-1387.
2. Sproule B, Brands B, Li S, Catz-Biro L. Changing patterns in opioid addiction. Canadian Family Physician 2009; 55: 68-69.e.5.
3. Lexchin J, Kohler JC. The danger of imperfect regulation: OxyContin use in the United States and Canada. International Journal of Risk & Safety in Medicine 2011; 23: 233-240. doi:10.3233/JRS-2011-0539
4. Lipman A. What have we learned from Oxycontin. Journal of Pain and Palliative Care Pharmacotherapy 2003;17(1): 1-4.
5. Calveson R. Prescription opioid-related issues in Northern Ontario. Toronto, ON: Centre for Addiction and Mental Health, 2010. Available: http://intraspec.ca/aboriginal/NothernOntarioArea ReportPrescription_April2010.pdf (Accessed 27 March 2012).
6. Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Canadian Medical Association Journal 2009); 181(12): 891-896.
7. Kelly L, Cromarty H, Minty B, Morgan A, Madden S, Hopman W et al. Incidence and implications of narcotic exposure in First Nations in Northwest Ontario. Canadian Family Physician 2011; 57: e441-447.
8. Health Canada. Evaluation strategies in Aboriginal substance abuse programs: A discussion. Ottawa: Health Canada, 1998. Available: http://www.hc-sc.gc.ca/fniah-spnia/pubs/substan/_ads/literary_ examen_review/index-eng.php#a1-1 (Accessed 16 July 2012).
9. Milloy M-J, Wood E, Reading C, Kane D, Monaner J, Kerr T. Elevated overdose mortality rates among First Nations individuals in a Canadian setting: A population based analysis. Addiction 2010; 105: 1962-1970. doi:10.1111/j.1360-0443.2010.03077.x
10. Maté G. In the realm of hungry ghosts. Toronto, ON: Random House of Canada Limited, 2008.
11. Callaghan RC, Culi R, Vettese LC, Taylor L. A gendered analysis of Canadian aboriginal individuals admitted to inpatient substance abuse detoxification: A three-year medical chart review. The American Journal on Addictions 2006; 15(5): 380-386.
12. Walker R, Cromarty H, Kelly L, St Pierre-Hansen N. Achieving cultural safety in Aboriginal health services: Implementation of a cross-cultural safety model in a hospital setting. Diversity in Health and Care 2009; 6: 11-22.
13. Institute of Medicine. Broadening the base of treatment for alcohol problems. Washington, DC: National Academy Press, 1990.
14. Jiwa A, Kelly L, St. Pierre-Hansen N. Healing the community to heal the individual: Literature review of Aboriginal communitybased alcohol and substance abuse programs. Canadian Family Physician 2008; 54: 1000-1000e-7.
15. Day E, Strang J. Outpatient versus inpatient opioid detoxification: A randomized controlled trial. Journal of Substance Abuse Treatment 2010; 40: 56-66.
16. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence (Review). The Cochrane Library 2005; Issue 2. Art. No.: CD004580. doi:10.1002/14651858. CD004580.pub2
17. Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine. Health Care Reform 2011; 171(5): 425-431
18. Horspool M, Seivewright N, Armitage C. Post-treatment outcomes of buprenorphine detoxification in community settings: A systematic review. European Addiction Research 2008; 14: 179-185.
19. College of Physicians and Surgeons of Ontario. Methadone maintenance program for opioid dependence. Toronto, ON: College of Physicians and Surgeons of Ontario, 2010. Available: http:// www.cpso.on.ca/policies/guidelines/default.aspx?id=1984 (Accessed 28 March 2012).
20. Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. Current Psychiatry Reports 2000; 2: 519-526.
21. Orman J, Keating G. Buprenorphine/naloxone: A review of its use in the treatment of opioid dependence. Drugs 2009; 69(5): 577-607.
22. Wesson D, Smith D. Buprenorphine in the treatment of opiate dependence. Journal of Psychoactive Drugs 2010, 42(2): 161-175.
23. Ling W, Hillhouse M, Domier C, Doraimaini G, Hunter J, Thomas C et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009; 104: 256-265.
24. Calysn D, Malcy J, Saxon A. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. Journal of Substance Abuse Treatment 2006; 30: 159-163.
25. Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous intramuscular and intranasal naloxone in human volunteers. Therapeutic Drug Monitoring 2008; 30(4): 490-496.
26. Lorimer N, Hoffman P, Chadhry HR. Nasal administration of naloxone for detection of opiate dependence. Journal of Psychiatry 1992; 26(1): 39-43.
27. Fudala P, Yu E, Macfadden W, Broadman C, Chiang N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug and Alcohol Dependence 1998; 50: 1-8.
28. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence 2007; 88(1): 75-78. doi:10.1016/j. drugalcdep.2006.09.012
29. Centre for Addiction and Mental Health. Clinical Opiate Withdrawal Scale (COWS) Flowsheet. Toronto: Centre for Addiction and Mental Health, 2011. Available: http://www.camh.net/ Publications/Resources_for_Professionals/clinic_toolkit_methado ne/clinic_toolkit_methadone_forms.html (Accessed 28 March 2012).
30. Provincial Council for Maternal and Child Health. Neonatal Abstinence Syndrome. Toronto: Provincial Council for Maternal and Child Health, 2011. Available: http://pcmch.on.ca/Clinical PracticeGuidelines/NeonatalAbstinenceSyndrome.aspx (Accessed 28 March 2012).
31. Wong S, Ordean A, Kahanj, M. Substance abuse in pregnancy. Journal of Obstetrics and Gynaecology Canada 2011; 33(4): 367-384.
32. Ebner N, Rohrmeister K, Winklbaur B, Baewert A, Jagsch R, Peternell A et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Dependence 2007; 87: 131-138.
33. Kaltenbach K. Exposure to opiates: Behavioral outcomes in preschool and school aged children. NIDA Monograph 1996; 164: 41. Available: archives.drugabuse.gov/pdf/monographs/.../230-241_ Kaltenbach.pdf (Accessed 28 August 2010).
34. Riley E, Infante M, Warren K. Fetal alcohol spectrum disorders: An overview. Neuropsychological Review 2011; 21: 73-80.
35. McKenzie D. Fetal alcohol syndrome: Canadian profile 1996. Ottawa: Canadian Centre of Substance Abuse, 1997